{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:35:20Z","timestamp":1793932520897,"version":"4.8.0"},"reference-count":249,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"DOI":"10.1007\/s00018-025-05668-y","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T15:11:41Z","timestamp":1744038701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["An update on mammalian and non-mammalian animal models for biomarker development in neurodegenerative disorders"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6087-3941","authenticated-orcid":false,"given":"Ribhav","family":"Mishra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"5668_CR1","doi-asserted-by":"crossref","unstructured":"Dawson TM, Golde TE, Lagier-Tourenne C (2018) Animal models of neurodegenerative diseases. Nat Neurosci 21(10):1370\u20131379","DOI":"10.1038\/s41593-018-0236-8"},{"issue":"3","key":"5668_CR2","doi-asserted-by":"publisher","first-page":"206","DOI":"10.7150\/ijms.5529","volume":"10","author":"R Greek","year":"2013","unstructured":"Greek R, Menache A (2013) Systematic reviews of animal models: methodology versus epistemology. Int J Med Sci 10(3):206\u2013221","journal-title":"Int J Med Sci"},{"issue":"8","key":"5668_CR3","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.2174\/138161212799315768","volume":"18","author":"I Moreno-Gonzalez","year":"2012","unstructured":"Moreno-Gonzalez I, Soto C (2012) Natural animal models of neurodegenerative protein misfolding diseases. Curr Pharm Des 18(8):1148\u20131158","journal-title":"Curr Pharm Des"},{"issue":"1","key":"5668_CR4","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s11064-019-02777-6","volume":"45","author":"T Roitbak","year":"2020","unstructured":"Roitbak T (2020) MicroRNAs and regeneration in animal models of CNS disorders. Neurochem Res 45(1):188\u2013203","journal-title":"Neurochem Res"},{"issue":"3","key":"5668_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.4103\/1673-5374.245464","volume":"14","author":"J-M Bourgognon","year":"2019","unstructured":"Bourgognon J-M, Steinert JR (2019) The metabolome identity: basis for discovery of biomarkers in neurodegeneration. Neural Regeneration Res 14(3):387\u2013390","journal-title":"Neural Regeneration Res"},{"issue":"5","key":"5668_CR6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1242\/dmm.030205","volume":"10","author":"AD Gitler","year":"2017","unstructured":"Gitler AD, Dhillon P, Shorter J (2017) Neurodegenerative disease: models, mechanisms, and a new hope. Dis Models Mech 10(5):499\u2013502","journal-title":"Dis Models Mech"},{"key":"5668_CR7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fnins.2015.00064","volume":"9","author":"J-M Verdier","year":"2015","unstructured":"Verdier J-M et al (2015) Lessons from the analysis of nonhuman primates for Understanding human aging and neurodegenerative diseases. Front NeuroSci 9:64","journal-title":"Front NeuroSci"},{"key":"5668_CR8","doi-asserted-by":"publisher","first-page":"1378620","DOI":"10.3389\/fneur.2024.1378620","volume":"15","author":"NJ Katchur","year":"2024","unstructured":"Katchur NJ, Notterman DA (2024) Recent insights from non-mammalian models of brain injuries: an emerging literature. Front Neurol 15:1378620","journal-title":"Front Neurol"},{"issue":"3","key":"5668_CR9","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.neuro.2008.04.006","volume":"29","author":"RT Peterson","year":"2008","unstructured":"Peterson RT et al (2008) Use of non-mammalian alternative models for neurotoxicological study. Neurotoxicology 29(3):546\u2013555","journal-title":"Neurotoxicology"},{"issue":"1","key":"5668_CR10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41576-023-00633-6","volume":"25","author":"S Yamamoto","year":"2024","unstructured":"Yamamoto S et al (2024) Integrating non-mammalian model organisms in the diagnosis of rare genetic diseases in humans. Nat Rev Genet 25(1):46\u201360","journal-title":"Nat Rev Genet"},{"issue":"11","key":"5668_CR11","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s00018-019-03055-y","volume":"76","author":"R Mishra","year":"2019","unstructured":"Mishra R et al (2019) LRSAM1 E3 ubiquitin ligase: molecular Neurobiological perspectives linked with brain diseases. Cell Mol Life Sci 76(11):2093\u20132110","journal-title":"Cell Mol Life Sci"},{"key":"5668_CR12","doi-asserted-by":"publisher","first-page":"105697","DOI":"10.1016\/j.biocel.2020.105697","volume":"120","author":"R Mishra","year":"2020","unstructured":"Mishra R et al (2020) Ubiquitin ligase LRSAM1 suppresses neurodegenerative diseases linked aberrant proteins induced cell death. Int J Biochem Cell Biol 120:105697","journal-title":"Int J Biochem Cell Biol"},{"key":"5668_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/978-1-60327-369-5_10","volume":"1027","author":"C Liu","year":"2013","unstructured":"Liu C et al (2013) Pronuclear microinjection and oviduct transfer procedures for Transgenic mouse production. Methods Mol Biol 1027:217\u2013232","journal-title":"Methods Mol Biol"},{"issue":"23","key":"5668_CR14","doi-asserted-by":"publisher","first-page":"13090","DOI":"10.1073\/pnas.231473498","volume":"98","author":"M Nagano","year":"2001","unstructured":"Nagano M et al (2001) Transgenic mice produced by retroviral transduction of male germ-line stem cells. Proc Natl Acad Sci U S A 98(23):13090\u201313095","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"5668_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s43141-023-00502-z","volume":"21","author":"WME Shakweer","year":"2023","unstructured":"Shakweer WME et al (2023) A review of Transgenic animal techniques and their applications. J Genet Eng Biotechnol 21(1):55","journal-title":"J Genet Eng Biotechnol"},{"issue":"4","key":"5668_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.5625\/lar.2018.34.4.147","volume":"34","author":"H Kim","year":"2018","unstructured":"Kim H et al (2018) Mouse Cre-LoxP system: general principles to determine tissue-specific roles of target genes. Lab Anim Res 34(4):147\u2013159","journal-title":"Lab Anim Res"},{"issue":"8","key":"5668_CR17","doi-asserted-by":"publisher","first-page":"a006239","DOI":"10.1101\/cshperspect.a006239","volume":"2","author":"R Mayeux","year":"2012","unstructured":"Mayeux R, Stern Y (2012) Epidemiology of alzheimer disease. Cold Spring Harbor Perspect Med 2(8):a006239","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"5668_CR18","doi-asserted-by":"crossref","unstructured":"Li X-L et al (2014) Behavioral and psychological symptoms in Alzheimer\u2019s disease. BioMed research international, 2014: pp. 927804\u2013927804","DOI":"10.1155\/2014\/927804"},{"issue":"4","key":"5668_CR19","first-page":"289","volume":"47","author":"RA Armstrong","year":"2009","unstructured":"Armstrong RA (2009) The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer\u2019s disease. Folia Neuropathol 47(4):289\u2013299","journal-title":"Folia Neuropathol"},{"issue":"5","key":"5668_CR20","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0197-4580(98)00080-3","volume":"19","author":"PR Mouton","year":"1998","unstructured":"Mouton PR et al (1998) Cognitive decline strongly correlates with cortical atrophy in Alzheimer\u2019s dementia. Neurobiol Aging 19(5):371\u2013377","journal-title":"Neurobiol Aging"},{"issue":"11","key":"5668_CR21","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1212\/01.wnl.0000344568.09360.31","volume":"72","author":"WJP Henneman","year":"2009","unstructured":"Henneman WJP et al (2009) Hippocampal atrophy rates in alzheimer disease: added value over whole brain volume measures. Neurology 72(11):999\u20131007","journal-title":"Neurology"},{"key":"5668_CR22","doi-asserted-by":"crossref","unstructured":"Murphy MP, LeVine H 3 (2010) Alzheimer\u2019s disease and the amyloid-beta peptide. J Alzheimer\u2019s Disease: JAD 19(1):311\u2013323","DOI":"10.3233\/JAD-2010-1221"},{"key":"5668_CR23","doi-asserted-by":"crossref","unstructured":"Brion JP et al Neurofibrillary tangles and Tau phosphorylation. Biochem Soc Symp 2001;(67):81\u201388","DOI":"10.1042\/bss0670081"},{"issue":"4","key":"5668_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/0891988710383571","volume":"23","author":"LM Bekris","year":"2010","unstructured":"Bekris LM et al (2010) Genetics of alzheimer disease. J Geriatr Psychiatr Neurol 23(4):213\u2013227","journal-title":"J Geriatr Psychiatr Neurol"},{"key":"5668_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1385\/JMN:23:1-2:105","volume":"23","author":"R Vassar","year":"2004","unstructured":"Vassar R (2004) Bace 1: the \u03b2-secretase enzyme in Alzheimer\u2019s disease. J Mol Neurosci 23:105\u2013113","journal-title":"J Mol Neurosci"},{"key":"5668_CR26","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1146\/annurev.genet.32.1.461","volume":"32","author":"DL Price","year":"1998","unstructured":"Price DL et al (1998) Alzheimer\u2019s disease: genetic studies and Transgenic models. Annu Rev Genet 32:461\u2013493","journal-title":"Annu Rev Genet"},{"issue":"11","key":"5668_CR27","doi-asserted-by":"publisher","first-page":"a006320","DOI":"10.1101\/cshperspect.a006320","volume":"2","author":"FM LaFerla","year":"2012","unstructured":"LaFerla FM, Green KN (2012) Animal models of alzheimer disease. Cold Spring Harbor Perspect Med 2(11):a006320","journal-title":"Cold Spring Harbor Perspect Med"},{"issue":"9","key":"5668_CR28","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/aps.2017.28","volume":"38","author":"G-F Chen","year":"2017","unstructured":"Chen G-F et al (2017) Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin 38(9):1205\u20131235","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"5668_CR29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10519-006-9118-z","volume":"37","author":"JL Eriksen","year":"2007","unstructured":"Eriksen JL, Janus CG (2007) Plaques, tangles, and memory loss in mouse models of neurodegeneration. Behav Genet 37(1):79\u2013100","journal-title":"Behav Genet"},{"issue":"6514","key":"5668_CR30","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/373523a0","volume":"373","author":"D Games","year":"1995","unstructured":"Games D et al (1995) Alzheimer-type neuropathology in Transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373(6514):523\u2013527","journal-title":"Nature"},{"issue":"5284","key":"5668_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1126\/science.274.5284.99","volume":"274","author":"K Hsiao","year":"1996","unstructured":"Hsiao K et al (1996) Correlative memory deficits, A\u03b2 elevation, and amyloid plaques in Transgenic mice. Science 274(5284):99\u2013103","journal-title":"Science"},{"issue":"24","key":"5668_CR32","doi-asserted-by":"publisher","first-page":"13287","DOI":"10.1073\/pnas.94.24.13287","volume":"94","author":"C Sturchler-Pierrat","year":"1997","unstructured":"Sturchler-Pierrat C et al (1997) Two amyloid precursor protein Transgenic mouse models with alzheimer disease-like pathology. Proc Natl Acad Sci U S A 94(24):13287\u201313292","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"5668_CR33","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1523\/JNEUROSCI.20-11-04050.2000","volume":"20","author":"L Mucke","year":"2000","unstructured":"Mucke L et al (2000) High-level neuronal expression of Abeta 1\u201342 in wild-type human amyloid protein precursor Transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20(11):4050\u20134058","journal-title":"J Neurosci"},{"issue":"24","key":"5668_CR34","doi-asserted-by":"publisher","first-page":"21562","DOI":"10.1074\/jbc.M100710200","volume":"276","author":"MA Chishti","year":"2001","unstructured":"Chishti MA et al (2001) Early-onset amyloid deposition and cognitive deficits in Transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 276(24):21562\u201321570","journal-title":"J Biol Chem"},{"issue":"1","key":"5668_CR35","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.neurobiolaging.2004.12.007","volume":"27","author":"A Lord","year":"2006","unstructured":"Lord A et al (2006) The Arctic alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in Transgenic mice. Neurobiol Aging 27(1):67\u201377","journal-title":"Neurobiol Aging"},{"issue":"36","key":"5668_CR36","doi-asserted-by":"publisher","first-page":"11393","DOI":"10.1523\/JNEUROSCI.2021-09.2009","volume":"29","author":"K Yamada","year":"2009","unstructured":"Yamada K et al (2009) Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J Neurosci 29(36):11393\u201311398","journal-title":"J Neurosci"},{"issue":"26","key":"5668_CR37","doi-asserted-by":"publisher","first-page":"8989","DOI":"10.1523\/JNEUROSCI.23-26-08989.2003","volume":"23","author":"JG Richards","year":"2003","unstructured":"Richards JG et al (2003) PS2APP Transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J Neurosci 23(26):8989\u20139003","journal-title":"J Neurosci"},{"issue":"2","key":"5668_CR38","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/hmg\/ddh019","volume":"13","author":"JL Jankowsky","year":"2003","unstructured":"Jankowsky JL et al (2003) Mutant presenilins specifically elevate the levels of the 42 residue \u03b2-amyloid peptide in vivo: evidence for augmentation of a 42-specific \u03b3 secretase. Hum Mol Genet 13(2):159\u2013170","journal-title":"Hum Mol Genet"},{"issue":"40","key":"5668_CR39","doi-asserted-by":"publisher","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","volume":"26","author":"H Oakley","year":"2006","unstructured":"Oakley H et al (2006) Intraneuronal \u03b2-Amyloid aggregates, neurodegeneration, and neuron loss in Transgenic mice with five Familial Alzheimer\u2019s disease mutations: potential factors in amyloid plaque formation. J Neurosci 26(40):10129\u201310140","journal-title":"J Neurosci"},{"issue":"5","key":"5668_CR40","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.tig.2006.03.007","volume":"22","author":"E McGowan","year":"2006","unstructured":"McGowan E, Eriksen J, Hutton M (2006) A decade of modeling Alzheimer\u2019s disease in Transgenic mice. Trends Genet 22(5):281\u2013289","journal-title":"Trends Genet"},{"issue":"4","key":"5668_CR41","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/78078","volume":"25","author":"J Lewis","year":"2000","unstructured":"Lewis J et al (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) Tau protein. Nat Genet 25(4):402\u2013405","journal-title":"Nat Genet"},{"issue":"3","key":"5668_CR42","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.neuron.2007.01.010","volume":"53","author":"Y Yoshiyama","year":"2007","unstructured":"Yoshiyama Y et al (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53(3):337\u2013351","journal-title":"Neuron"},{"issue":"5733","key":"5668_CR43","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1126\/science.1113694","volume":"309","author":"K SantaCruz","year":"2005","unstructured":"SantaCruz K et al (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309(5733):476\u2013481","journal-title":"Science"},{"issue":"3","key":"5668_CR44","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","volume":"39","author":"S Oddo","year":"2003","unstructured":"Oddo S et al (2003) Triple-transgenic model of Alzheimer\u2019s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39(3):409\u2013421","journal-title":"Neuron"},{"issue":"34","key":"5668_CR45","doi-asserted-by":"publisher","first-page":"12754","DOI":"10.1074\/jbc.RA119.009487","volume":"294","author":"T Saito","year":"2019","unstructured":"Saito T et al (2019) Humanization of the entire murine Mapt gene provides a murine model of pathological human Tau propagation. J Biol Chem 294(34):12754\u201312765","journal-title":"J Biol Chem"},{"issue":"7","key":"5668_CR46","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/ncb1901","volume":"11","author":"F Clavaguera","year":"2009","unstructured":"Clavaguera F et al (2009) Transmission and spreading of tauopathy in Transgenic mouse brain. Nat Cell Biol 11(7):909\u2013913","journal-title":"Nat Cell Biol"},{"issue":"5","key":"5668_CR47","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00401-014-1254-6","volume":"127","author":"Z Ahmed","year":"2014","unstructured":"Ahmed Z et al (2014) A novel in vivo model of Tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol 127(5):667\u2013683","journal-title":"Acta Neuropathol"},{"issue":"7880","key":"5668_CR48","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41586-021-03911-7","volume":"598","author":"Y Shi","year":"2021","unstructured":"Shi Y et al (2021) Structure-based classification of tauopathies. Nature 598(7880):359\u2013363","journal-title":"Nature"},{"issue":"8","key":"5668_CR49","doi-asserted-by":"publisher","first-page":"656","DOI":"10.2174\/156720510793611592","volume":"7","author":"K Iqbal","year":"2010","unstructured":"Iqbal K et al (2010) Tau in alzheimer disease and related tauopathies. Curr Alzheimer Res 7(8):656\u2013664","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"5668_CR50","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13024-023-00601-y","volume":"18","author":"K Wenger","year":"2023","unstructured":"Wenger K et al (2023) Common mouse models of tauopathy reflect early but not late human disease. Mol Neurodegener 18(1):10","journal-title":"Mol Neurodegener"},{"issue":"6645","key":"5668_CR51","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG et al (1997) Alpha-synuclein in lewy bodies. Nature 388(6645):839\u2013840","journal-title":"Nature"},{"issue":"6","key":"5668_CR52","doi-asserted-by":"publisher","first-page":"a008870","DOI":"10.1101\/cshperspect.a008870","volume":"2","author":"J Massano","year":"2012","unstructured":"Massano J, Bhatia KP (2012) Clinical approach to Parkinson\u2019s disease: features, diagnosis, and principles of management. Cold Spring Harbor Perspect Med 2(6):a008870\u2013a008870","journal-title":"Cold Spring Harbor Perspect Med"},{"issue":"Pt B","key":"5668_CR53","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.expneurol.2017.04.008","volume":"298","author":"L Scott","year":"2017","unstructured":"Scott L, Dawson VL, Dawson TM (2017) Trumping neurodegeneration: targeting common pathways regulated by autosomal recessive Parkinson\u2019s disease genes. Exp Neurol 298(Pt B):191\u2013201","journal-title":"Exp Neurol"},{"key":"5668_CR54","doi-asserted-by":"crossref","unstructured":"Chang D, et al (2017) A meta-analysis of genome-wide association studies identifies 17 new Parkinson\u2019s disease risk loci. Nature Genetics 49(10):1511\u20131516","DOI":"10.1038\/ng.3955"},{"key":"5668_CR55","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fnana.2014.00155","volume":"8","author":"J Blesa","year":"2014","unstructured":"Blesa J, Przedborski S (2014) Parkinson\u2019s disease: animal models and dopaminergic cell vulnerability. Front Neuroanat 8:155","journal-title":"Front Neuroanat"},{"issue":"12","key":"5668_CR56","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/81834","volume":"3","author":"R Betarbet","year":"2000","unstructured":"Betarbet R et al (2000) Chronic systemic pesticide exposure reproduces features of Parkinson\u2019s disease. Nat Neurosci 3(12):1301\u20131306","journal-title":"Nat Neurosci"},{"issue":"1\u20132","key":"5668_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0006-8993(98)01192-5","volume":"823","author":"AI Brooks","year":"1999","unstructured":"Brooks AI et al (1999) Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res 823(1\u20132):1\u201310","journal-title":"Brain Res"},{"issue":"1","key":"5668_CR58","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/0006-8993(96)00995-X","volume":"738","author":"PK Sonsalla","year":"1996","unstructured":"Sonsalla PK et al (1996) Treatment of mice with methamphetamine produces cell loss in the substantia Nigra. Brain Res 738(1):172\u2013175","journal-title":"Brain Res"},{"issue":"14","key":"5668_CR59","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1002\/mds.25646","volume":"28","author":"G Costa","year":"2013","unstructured":"Costa G et al (2013) MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA-pretreated mice. Mov Disord 28(14):1957\u20131965","journal-title":"Mov Disord"},{"issue":"1","key":"5668_CR60","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.molbrainres.2005.01.012","volume":"134","author":"M Shimoji","year":"2005","unstructured":"Shimoji M et al (2005) Absence of inclusion body formation in the MPTP mouse model of Parkinson\u2019s disease. Brain Res Mol Brain Res 134(1):103\u2013108","journal-title":"Brain Res Mol Brain Res"},{"key":"5668_CR61","doi-asserted-by":"crossref","unstructured":"Masini D et al (2021) A Guide to the Generation of a 6-Hydroxydopamine Mouse Model of Parkinson\u2019s Disease for the Study of Non-Motor Symptoms. Biomedicines, 9(6)","DOI":"10.3390\/biomedicines9060598"},{"issue":"5","key":"5668_CR62","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.neuro.2012.05.011","volume":"33","author":"C Freire","year":"2012","unstructured":"Freire C, Koifman S (2012) Pesticide exposure and Parkinson\u2019s disease: epidemiological evidence of association. Neurotoxicology 33(5):947\u2013971","journal-title":"Neurotoxicology"},{"issue":"34","key":"5668_CR63","doi-asserted-by":"publisher","first-page":"10756","DOI":"10.1523\/JNEUROSCI.23-34-10756.2003","volume":"23","author":"TB Sherer","year":"2003","unstructured":"Sherer TB et al (2003) Mechanism of toxicity in rotenone models of Parkinson\u2019s disease. J Neurosci 23(34):10756\u201310764","journal-title":"J Neurosci"},{"issue":"9","key":"5668_CR64","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/nrn.2017.75","volume":"18","author":"JB Koprich","year":"2017","unstructured":"Koprich JB, Kalia LV, Brotchie JM (2017) Animal models of \u03b1-synucleinopathy for Parkinson disease drug development. Nat Rev Neurosci 18(9):515\u2013529","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"5668_CR65","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/mds.25108","volume":"28","author":"E Bezard","year":"2013","unstructured":"Bezard E et al (2013) Animal models of Parkinson\u2019s disease: limits and relevance to neuroprotection studies. Mov Disord 28(1):61\u201370","journal-title":"Mov Disord"},{"issue":"4","key":"5668_CR66","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0896-6273(02)00682-7","volume":"34","author":"BI Giasson","year":"2002","unstructured":"Giasson BI et al (2002) Neuronal \u03b1-synucleinopathy with severe movement disorder in mice expressing A53T human \u03b1-synuclein. Neuron 34(4):521\u2013533","journal-title":"Neuron"},{"key":"5668_CR67","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.expneurol.2012.11.007","volume":"240","author":"JR Cannon","year":"2013","unstructured":"Cannon JR et al (2013) Expression of human E46K-mutated \u03b1-synuclein in BAC-transgenic rats replicates early-stage Parkinson\u2019s disease features and enhances vulnerability to mitochondrial impairment. Exp Neurol 240:44\u201356","journal-title":"Exp Neurol"},{"key":"5668_CR68","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.nbd.2013.10.005","volume":"62","author":"TN Taylor","year":"2014","unstructured":"Taylor TN et al (2014) Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P \u03b1-synuclein BAC Transgenic mouse. Neurobiol Dis 62:193\u2013207","journal-title":"Neurobiol Dis"},{"issue":"3","key":"5668_CR69","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/j.1750-3639.2003.tb00035.x","volume":"13","author":"E Lauwers","year":"2003","unstructured":"Lauwers E et al (2003) Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein. Brain Pathol 13(3):364\u2013372","journal-title":"Brain Pathol"},{"issue":"6109","key":"5668_CR70","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.1227157","volume":"338","author":"KC Luk","year":"2012","unstructured":"Luk KC et al (2012) Pathological \u03b1-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338(6109):949\u2013953","journal-title":"Science"},{"issue":"3","key":"5668_CR71","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/ana.24066","volume":"75","author":"A Recasens","year":"2014","unstructured":"Recasens A et al (2014) Lewy body extracts from Parkinson disease brains trigger \u03b1-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol 75(3):351\u2013362","journal-title":"Ann Neurol"},{"issue":"1","key":"5668_CR72","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1042\/BST20160238","volume":"45","author":"M Volta","year":"2017","unstructured":"Volta M, Melrose H (2017) LRRK2 mouse models: dissecting the behavior, striatal neurochemistry and neurophysiology of PD pathogenesis. Biochem Soc Trans 45(1):113\u2013122","journal-title":"Biochem Soc Trans"},{"issue":"7","key":"5668_CR73","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1073\/pnas.1712648115","volume":"115","author":"Y Xiong","year":"2018","unstructured":"Xiong Y et al (2018) Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S Transgenic mice. Proc Natl Acad Sci U S A 115(7):1635\u20131640","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5668_CR74","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/978-3-319-49969-7_9","volume":"14","author":"Y Xiong","year":"2017","unstructured":"Xiong Y, Dawson TM, Dawson VL (2017) Models of LRRK2-Associated Parkinson\u2019s disease. Adv Neurobiol 14:163\u2013191","journal-title":"Adv Neurobiol"},{"issue":"5","key":"5668_CR75","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.neuron.2010.04.034","volume":"66","author":"TM Dawson","year":"2010","unstructured":"Dawson TM, Ko HS, Dawson VL (2010) Genetic animal models of Parkinson\u2019s disease. Neuron 66(5):646\u2013661","journal-title":"Neuron"},{"issue":"4","key":"5668_CR76","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.celrep.2016.12.090","volume":"18","author":"Y Lee","year":"2017","unstructured":"Lee Y et al (2017) PINK1 primes Parkin-Mediated ubiquitination of PARIS in dopaminergic neuronal survival. Cell Rep 18(4):918\u2013932","journal-title":"Cell Rep"},{"issue":"4","key":"5668_CR77","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.neuron.2005.01.041","volume":"45","author":"MS Goldberg","year":"2005","unstructured":"Goldberg MS et al (2005) Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the Familial Parkinsonism-linked gene DJ-1. Neuron 45(4):489\u2013496","journal-title":"Neuron"},{"issue":"14","key":"5668_CR78","doi-asserted-by":"publisher","first-page":"5215","DOI":"10.1073\/pnas.0501282102","volume":"102","author":"RH Kim","year":"2005","unstructured":"Kim RH et al (2005) Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci U S A 102(14):5215\u20135220","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5668_CR79","unstructured":"Opal P, Ashizawa T et al (1993) Spinocerebellar Ataxia Type 1, in GeneReviews(\u00ae), M.P. Adam, Editors. University of Washington, Seattle Copyright \u00a9 1993\u20132020, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.: Seattle (WA)"},{"issue":"10","key":"5668_CR80","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41582-018-0051-6","volume":"14","author":"T Ashizawa","year":"2018","unstructured":"Ashizawa T, \u00d6z G, Paulson HL (2018) Spinocerebellar ataxias: prospects and challenges for therapy development. Nat Reviews Neurol 14(10):590\u2013605","journal-title":"Nat Reviews Neurol"},{"issue":"3","key":"5668_CR81","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/ng0793-221","volume":"4","author":"HT Orr","year":"1993","unstructured":"Orr HT et al (1993) Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat Genet 4(3):221\u2013226","journal-title":"Nat Genet"},{"issue":"4","key":"5668_CR82","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/ng0894-513","volume":"7","author":"S Banfi","year":"1994","unstructured":"Banfi S et al (1994) Identification and characterization of the gene causing type 1 spinocerebellar ataxia. Nat Genet 7(4):513\u2013520","journal-title":"Nat Genet"},{"issue":"4","key":"5668_CR83","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/ana.410390412","volume":"39","author":"LG Goldfarb","year":"1996","unstructured":"Goldfarb LG et al (1996) Unstable triplet repeat and phenotypic variability of spinocerebellar ataxia type 1. Ann Neurol 39(4):500\u2013506","journal-title":"Ann Neurol"},{"issue":"7","key":"5668_CR84","doi-asserted-by":"publisher","first-page":"e1003648","DOI":"10.1371\/journal.pgen.1003648","volume":"9","author":"RP Menon","year":"2013","unstructured":"Menon RP et al (2013) The role of interruptions in PolyQ in the pathology of SCA1. PLoS Genet 9(7):e1003648\u2013e1003648","journal-title":"PLoS Genet"},{"issue":"2","key":"5668_CR85","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/502","volume":"19","author":"CJ Cummings","year":"1998","unstructured":"Cummings CJ et al (1998) Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat Genet 19(2):148\u2013154","journal-title":"Nat Genet"},{"issue":"6","key":"5668_CR86","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/0092-8674(95)90273-2","volume":"82","author":"EN Burright","year":"1995","unstructured":"Burright EN et al (1995) SCA1 Transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 82(6):937\u2013948","journal-title":"Cell"},{"issue":"40","key":"5668_CR87","doi-asserted-by":"publisher","first-page":"8853","DOI":"10.1523\/JNEUROSCI.2978-04.2004","volume":"24","author":"T Zu","year":"2004","unstructured":"Zu T et al (2004) Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 Transgenic mice. J Neuroscience: Official J Soc Neurosci 24(40):8853\u20138861","journal-title":"J Neuroscience: Official J Soc Neurosci"},{"issue":"6","key":"5668_CR88","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/S0896-6273(02)00733-X","volume":"34","author":"K Watase","year":"2002","unstructured":"Watase K et al (2002) A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron 34(6):905\u2013919","journal-title":"Neuron"},{"issue":"5","key":"5668_CR89","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/hmg\/9.5.779","volume":"9","author":"D Lorenzetti","year":"2000","unstructured":"Lorenzetti D et al (2000) Repeat instability and motor incoordination in mice with a targeted expanded CAG repeat in the Sca1 locus. Hum Mol Genet 9(5):779\u2013785","journal-title":"Hum Mol Genet"},{"issue":"3","key":"5668_CR90","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3233\/JAD-190714","volume":"73","author":"X Wang","year":"2020","unstructured":"Wang X et al (2020) Amyloid-\u03b2 as a blood biomarker for Alzheimer\u2019s disease: A review of recent literature. J Alzheimers Dis 73(3):819\u2013832","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"5668_CR91","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1523\/JNEUROSCI.21-02-00372.2001","volume":"21","author":"T Kawarabayashi","year":"2001","unstructured":"Kawarabayashi T et al (2001) Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 Transgenic mouse model of Alzheimer\u2019s disease. J Neurosci 21(2):372\u2013381","journal-title":"J Neurosci"},{"issue":"3","key":"5668_CR92","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ana.20730","volume":"59","author":"AM Fagan","year":"2006","unstructured":"Fagan AM et al (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59(3):512\u2013519","journal-title":"Ann Neurol"},{"issue":"2","key":"5668_CR93","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1046\/j.1471-4159.2002.00889.x","volume":"81","author":"RB DeMattos","year":"2002","unstructured":"DeMattos RB et al (2002) Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer\u2019s disease. J Neurochem 81(2):229\u2013236","journal-title":"J Neurochem"},{"issue":"1","key":"5668_CR94","doi-asserted-by":"publisher","first-page":"e14408","DOI":"10.15252\/emmm.202114408","volume":"14","author":"A Leuzy","year":"2022","unstructured":"Leuzy A et al (2022) Blood-based biomarkers for Alzheimer\u2019s disease. EMBO Mol Med 14(1):e14408","journal-title":"EMBO Mol Med"},{"issue":"5","key":"5668_CR95","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.tips.2015.03.002","volume":"36","author":"K Blennow","year":"2015","unstructured":"Blennow K et al (2015) Amyloid biomarkers in Alzheimer\u2019s disease. Trends Pharmacol Sci 36(5):297\u2013309","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"5668_CR96","doi-asserted-by":"publisher","first-page":"e0227618","DOI":"10.1371\/journal.pone.0227618","volume":"15","author":"DE Kwak","year":"2020","unstructured":"Kwak DE et al (2020) Alterations of aqueous humor A\u03b2 levels in A\u03b2-infused and Transgenic mouse models of alzheimer disease. PLoS ONE 15(1):e0227618","journal-title":"PLoS ONE"},{"issue":"9365","key":"5668_CR97","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/S0140-6736(03)12981-9","volume":"361","author":"LE Goldstein","year":"2003","unstructured":"Goldstein LE et al (2003) Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer\u2019s disease. Lancet 361(9365):1258\u20131265","journal-title":"Lancet"},{"issue":"12","key":"5668_CR98","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.1523\/JNEUROSCI.21-12-04183.2001","volume":"21","author":"D Pratic\u00f2","year":"2001","unstructured":"Pratic\u00f2 D et al (2001) Increased lipid peroxidation precedes amyloid plaque formation in an animal model of alzheimer amyloidosis. J Neurosci 21(12):4183\u20134187","journal-title":"J Neurosci"},{"issue":"1","key":"5668_CR99","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s12017-010-8126-6","volume":"13","author":"TJ Montine","year":"2011","unstructured":"Montine TJ et al (2011) Increased cerebrospinal fluid F2-isoprostanes are associated with aging and latent Alzheimer\u2019s disease as identified by biomarkers. Neuromolecular Med 13(1):37\u201343","journal-title":"Neuromolecular Med"},{"issue":"Suppl 2","key":"5668_CR100","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3233\/JAD-2011-110161","volume":"24","author":"DM Barten","year":"2011","unstructured":"Barten DM et al (2011) Tau Transgenic mice as models for cerebrospinal fluid Tau biomarkers. J Alzheimers Dis 24(Suppl 2):127\u2013141","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"5668_CR101","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze S et al (2023) Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain 146(4):1592\u20131601","journal-title":"Brain"},{"issue":"12","key":"5668_CR102","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1038\/tp.2013.102","volume":"3","author":"A Trueba-S\u00e1iz","year":"2013","unstructured":"Trueba-S\u00e1iz A et al (2013) Loss of serum IGF-I input to the brain as an early biomarker of disease onset in alzheimer mice. Translational Psychiatry 3(12):e330\u2013e330","journal-title":"Translational Psychiatry"},{"key":"5668_CR103","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3233\/JAD-142805","volume":"45","author":"Y Sun","year":"2015","unstructured":"Sun Y et al (2015) Translational study of Alzheimer\u2019s disease (AD) biomarkers from brain tissues in A\u03b2PP\/PS1 mice and serum of AD patients. J Alzheimers Dis 45:269\u2013282","journal-title":"J Alzheimers Dis"},{"key":"5668_CR104","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3389\/fnins.2018.00612","volume":"12","author":"FN Emamzadeh","year":"2018","unstructured":"Emamzadeh FN, Surguchov A (2018) Parkinson\u2019s disease: biomarkers, treatment, and risk factors. Front Neurosci 12:612","journal-title":"Front Neurosci"},{"issue":"5","key":"5668_CR105","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/jcp.22467","volume":"226","author":"Y Kikuchi","year":"2011","unstructured":"Kikuchi Y et al (2011) Urinary 8-OHdG elevations in a partial lesion rat model of Parkinson\u2019s disease correlate with behavioral symptoms and nigrostriatal dopaminergic depletion. J Cell Physiol 226(5):1390\u20131398","journal-title":"J Cell Physiol"},{"issue":"2","key":"5668_CR106","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1006\/nbdi.2002.0466","volume":"9","author":"A Kikuchi","year":"2002","unstructured":"Kikuchi A et al (2002) Systemic increase of oxidative nucleic acid damage in Parkinson\u2019s disease and multiple system atrophy. Neurobiol Dis 9(2):244\u2013248","journal-title":"Neurobiol Dis"},{"issue":"6","key":"5668_CR107","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1212\/01.WNL.0000154597.24838.6B","volume":"64","author":"S Sato","year":"2005","unstructured":"Sato S, Mizuno Y, Hattori N (2005) Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease. Neurology 64(6):1081\u20131083","journal-title":"Neurology"},{"issue":"3","key":"5668_CR108","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.neulet.2010.08.007","volume":"483","author":"YO Akazawa","year":"2010","unstructured":"Akazawa YO et al (2010) Elevation of oxidized DJ-1 in the brain and erythrocytes of Parkinson disease model animals. Neurosci Lett 483(3):201\u2013205","journal-title":"Neurosci Lett"},{"issue":"16","key":"5668_CR109","doi-asserted-by":"publisher","first-page":"10816","DOI":"10.1074\/jbc.M509079200","volume":"281","author":"J Choi","year":"2006","unstructured":"Choi J et al (2006) Oxidative damage of DJ-1 is linked to sporadic Parkinson and alzheimer diseases. J Biol Chem 281(16):10816\u201310824","journal-title":"J Biol Chem"},{"key":"5668_CR110","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s40478-014-0176-9","volume":"2","author":"R Gir\u00e1ldez-P\u00e9rez","year":"2014","unstructured":"Gir\u00e1ldez-P\u00e9rez R et al (2014) Models of \u03b1-synuclein aggregation in Parkinson\u2019s disease. Acta Neuropathol Commun 2:176\u2013176","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"5668_CR111","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/0304-3940(82)90390-1","volume":"33","author":"TL Perry","year":"1982","unstructured":"Perry TL, Godin DV, Hansen S (1982) Parkinson\u2019s disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 33(3):305\u2013310","journal-title":"Neurosci Lett"},{"issue":"3","key":"5668_CR112","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ana.410360305","volume":"36","author":"J Sian","year":"1994","unstructured":"Sian J et al (1994) Alterations in glutathione levels in Parkinson\u2019s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36(3):348\u2013355","journal-title":"Ann Neurol"},{"issue":"6","key":"5668_CR113","doi-asserted-by":"publisher","first-page":"e99898","DOI":"10.1371\/journal.pone.0099898","volume":"9","author":"M Damiano","year":"2014","unstructured":"Damiano M et al (2014) Tissue- and cell-specific mitochondrial defect in Parkin-deficient mice. PLoS ONE 9(6):e99898\u2013e99898","journal-title":"PLoS ONE"},{"issue":"3","key":"5668_CR114","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s12031-012-9904-4","volume":"49","author":"SJ Mullett","year":"2013","unstructured":"Mullett SJ et al (2013) DJ-1 expression modulates astrocyte-mediated protection against neuronal oxidative stress. J Mol Neurosci 49(3):507\u2013511","journal-title":"J Mol Neurosci"},{"issue":"3","key":"5668_CR115","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/brain\/awq008","volume":"133","author":"Z Hong","year":"2010","unstructured":"Hong Z et al (2010) DJ-1 and \u03b1-synuclein in human cerebrospinal fluid as biomarkers of Parkinson\u2019s disease. Brain 133(3):713\u2013726","journal-title":"Brain"},{"issue":"1","key":"5668_CR116","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/srep00954","volume":"2","author":"X Lin","year":"2012","unstructured":"Lin X et al (2012) DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease. Sci Rep 2(1):954","journal-title":"Sci Rep"},{"issue":"34","key":"5668_CR117","doi-asserted-by":"publisher","first-page":"54215","DOI":"10.18632\/oncotarget.11090","volume":"7","author":"CC Chiu","year":"2016","unstructured":"Chiu CC et al (2016) Increased Rab35 expression is a potential biomarker and implicated in the pathogenesis of Parkinson\u2019s disease. Oncotarget 7(34):54215\u201354227","journal-title":"Oncotarget"},{"issue":"1","key":"5668_CR118","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41598-020-57938-3","volume":"10","author":"A Alieva","year":"2020","unstructured":"Alieva A et al (2020) VCP expression decrease as a biomarker of preclinical and early clinical stages of Parkinson\u2019s disease. Sci Rep 10(1):827","journal-title":"Sci Rep"},{"key":"5668_CR119","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.neuroscience.2012.02.001","volume":"208","author":"F Gillardon","year":"2012","unstructured":"Gillardon F, Schmid R, Draheim H (2012) Parkinson\u2019s disease-linked leucine-rich repeat kinase 2 (R1441G) mutation increases Proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience 208:41\u201348","journal-title":"Neuroscience"},{"key":"5668_CR120","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jneuroim.2015.04.014","volume":"283","author":"E Dursun","year":"2015","unstructured":"Dursun E et al (2015) The Interleukin 1 alpha, Interleukin 1 beta, Interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer\u2019s disease, mild cognitive impairment or Parkinson\u2019s disease. J Neuroimmunol 283:50\u201357","journal-title":"J Neuroimmunol"},{"issue":"9","key":"5668_CR121","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1212\/WNL.0000000000001308","volume":"84","author":"Y Hu","year":"2015","unstructured":"Hu Y et al (2015) Parkinson disease with REM sleep behavior disorder: features, \u03b1-synuclein, and inflammation. Neurology 84(9):888\u2013894","journal-title":"Neurology"},{"issue":"1","key":"5668_CR122","doi-asserted-by":"publisher","first-page":"e16038","DOI":"10.1371\/journal.pone.0016038","volume":"6","author":"RS Akundi","year":"2011","unstructured":"Akundi RS et al (2011) Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice. PLoS ONE 6(1):e16038","journal-title":"PLoS ONE"},{"issue":"1","key":"5668_CR123","doi-asserted-by":"publisher","first-page":"38","DOI":"10.5607\/en.2013.22.1.38","volume":"22","author":"J Kim","year":"2013","unstructured":"Kim J et al (2013) PINK1 deficiency enhances inflammatory cytokine release from acutely prepared brain slices. Experimental Neurobiol 22(1):38","journal-title":"Experimental Neurobiol"},{"issue":"1\u20132","key":"5668_CR124","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/0304-3940(94)90746-3","volume":"165","author":"M Mogi","year":"1994","unstructured":"Mogi M et al (1994) Tumor necrosis factor-\u03b1 (TNF-\u03b1) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165(1\u20132):208\u2013210","journal-title":"Neurosci Lett"},{"issue":"1\u20132","key":"5668_CR125","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0304-3940(94)90684-X","volume":"172","author":"G Boka","year":"1994","unstructured":"Boka G et al (1994) Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson\u2019s disease. Neurosci Lett 172(1\u20132):151\u2013154","journal-title":"Neurosci Lett"},{"issue":"1","key":"5668_CR126","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13024-018-0261-9","volume":"13","author":"LJA Toonen","year":"2018","unstructured":"Toonen LJA et al (2018) Transcriptional profiling and biomarker identification reveal tissue specific effects of expanded ataxin-3 in a spinocerebellar ataxia type 3 mouse model. Mol Neurodegener 13(1):31","journal-title":"Mol Neurodegener"},{"issue":"7","key":"5668_CR127","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/mds.26238","volume":"30","author":"M Raposo","year":"2015","unstructured":"Raposo M et al (2015) Novel candidate blood-based transcriptional biomarkers of Machado-Joseph disease. Mov Disord 30(7):968\u2013975","journal-title":"Mov Disord"},{"issue":"7","key":"5668_CR128","doi-asserted-by":"publisher","first-page":"e11803","DOI":"10.15252\/emmm.201911803","volume":"12","author":"C Wilke","year":"2020","unstructured":"Wilke C et al (2020) Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice. EMBO Mol Med 12(7):e11803","journal-title":"EMBO Mol Med"},{"key":"5668_CR129","doi-asserted-by":"crossref","unstructured":"Wilke C et al (2022) Levels of neurofilament light at the preataxic and ataxic stages of spinocerebellar ataxia type 1. Neurology, 98(20): p. e1985-e1996.","DOI":"10.1212\/WNL.0000000000200257"},{"issue":"7","key":"5668_CR130","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1007\/s00415-018-8893-9","volume":"265","author":"C Wilke","year":"2018","unstructured":"Wilke C et al (2018) Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study. J Neurol 265(7):1618\u20131624","journal-title":"J Neurol"},{"issue":"7","key":"5668_CR131","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.cell.2006.11.038","volume":"127","author":"YC Lam","year":"2006","unstructured":"Lam YC et al (2006) ATAXIN-1 interacts with the repressor capicua in its native complex to cause SCA1 neuropathology. Cell 127(7):1335\u20131347","journal-title":"Cell"},{"issue":"11","key":"5668_CR132","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/nm.2494","volume":"17","author":"M Cvetanovic","year":"2011","unstructured":"Cvetanovic M et al (2011) Vascular endothelial growth factor ameliorates the ataxic phenotype in a mouse model of spinocerebellar ataxia type 1. Nat Med 17(11):1445\u20131447","journal-title":"Nat Med"},{"issue":"20","key":"5668_CR133","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.3390\/cells11203323","volume":"11","author":"J-G Rosa","year":"2022","unstructured":"Rosa J-G et al (2022) Spatial and Temporal diversity of astrocyte phenotypes in spinocerebellar ataxia type 1 mice. Cells 11(20):3323","journal-title":"Cells"},{"key":"5668_CR134","doi-asserted-by":"crossref","unstructured":"Warren WC et al (2020) Sequence diversity analyses of an improved rhesus macaque genome enhance its biomedical utility. Science, 370(6523)","DOI":"10.1126\/science.abc6617"},{"key":"5668_CR135","doi-asserted-by":"crossref","unstructured":"Worley KC et al (2014) The common marmoset genome provides insight into primate biology and evolution. Nature Genetics, 46(8):850\u2013857","DOI":"10.1038\/ng.3042"},{"issue":"52","key":"5668_CR136","doi-asserted-by":"publisher","first-page":"26224","DOI":"10.1073\/pnas.1912954116","volume":"116","author":"RU Haque","year":"2019","unstructured":"Haque RU, Levey AI (2019) Alzheimer\u2019s disease: A clinical perspective and future nonhuman primate research opportunities. Proc Natl Acad Sci 116(52):26224\u201326229","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"5668_CR137","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ana.10156","volume":"51","author":"MS Albert","year":"2002","unstructured":"Albert MS (2002) Memory decline: the boundary between aging and age-related disease. Ann Neurol 51(3):282\u2013284","journal-title":"Ann Neurol"},{"issue":"52","key":"5668_CR138","doi-asserted-by":"publisher","first-page":"26239","DOI":"10.1073\/pnas.1902301116","volume":"116","author":"D Beckman","year":"2019","unstructured":"Beckman D et al (2019) Oligomeric A\u03b2 in the monkey brain impacts synaptic integrity and induces accelerated cortical aging. Proc Natl Acad Sci U S A 116(52):26239\u201326246","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"5668_CR139","doi-asserted-by":"publisher","first-page":"e12978","DOI":"10.1111\/acel.12978","volume":"18","author":"J Zhang","year":"2019","unstructured":"Zhang J et al (2019) Brains of rhesus monkeys display A\u03b2 deposits and glial pathology while lacking A\u03b2 dimers and other Alzheimer\u2019s pathologies. Aging Cell 18(4):e12978","journal-title":"Aging Cell"},{"issue":"41","key":"5668_CR140","doi-asserted-by":"publisher","first-page":"13629","DOI":"10.1523\/JNEUROSCI.1353-14.2014","volume":"34","author":"L Forny-Germano","year":"2014","unstructured":"Forny-Germano L et al (2014) Alzheimer\u2019s disease-like pathology induced by amyloid-\u03b2 oligomers in nonhuman primates. J Neurosci 34(41):13629\u201313643","journal-title":"J Neurosci"},{"key":"5668_CR141","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3389\/fnagi.2014.00313","volume":"6","author":"HS Darusman","year":"2014","unstructured":"Darusman HS et al (2014) Amyloid Beta1-42 and the phoshorylated Tau threonine 231 in brains of aged cynomolgus monkeys (Macaca fascicularis). Front Aging Neurosci 6:313","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"5668_CR142","doi-asserted-by":"publisher","first-page":"e12289","DOI":"10.1002\/trc2.12289","volume":"8","author":"EL Robertson","year":"2022","unstructured":"Robertson EL et al (2022) Characterization of cerebrospinal fluid biomarkers associated with neurodegenerative diseases in healthy cynomolgus and rhesus macaque monkeys. Alzheimers Dement (N Y) 8(1):e12289","journal-title":"Alzheimers Dement (N Y)"},{"issue":"14","key":"5668_CR143","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1073\/pnas.80.14.4546","volume":"80","author":"RS Burns","year":"1983","unstructured":"Burns RS et al (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the Pars compacta of the substantia Nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A 80(14):4546\u20134550","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1\u20133","key":"5668_CR144","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0304-3940(84)90467-1","volume":"50","author":"P Jenner","year":"1984","unstructured":"Jenner P et al (1984) 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci Lett 50(1\u20133):85\u201390","journal-title":"Neurosci Lett"},{"issue":"6","key":"5668_CR145","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/0028-3908(85)90070-X","volume":"24","author":"A Crossman","year":"1985","unstructured":"Crossman A, Mitchell I, Sambrook M (1985) Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)\u2014induced parkinsonism in the macaque monkey. Neuropharmacology 24(6):587\u2013591","journal-title":"Neuropharmacology"},{"issue":"1\u20132","key":"5668_CR146","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/0006-8993(90)90069-N","volume":"519","author":"J Schneider","year":"1990","unstructured":"Schneider J, Kovelowski C (1990) Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Brain Res 519(1\u20132):122\u2013128","journal-title":"Brain Res"},{"issue":"2","key":"5668_CR147","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S0014-4886(03)00139-0","volume":"183","author":"A Eslamboli","year":"2003","unstructured":"Eslamboli A et al (2003) Sensorimotor deficits in a unilateral intrastriatal 6-OHDA partial lesion model of Parkinson\u2019s disease in marmoset monkeys. Exp Neurol 183(2):418\u2013429","journal-title":"Exp Neurol"},{"issue":"4","key":"5668_CR148","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1523\/JNEUROSCI.4421-04.2005","volume":"25","author":"A Eslamboli","year":"2005","unstructured":"Eslamboli A et al (2005) Continuous low-level glial cell line-derived neurotrophic factor delivery using Recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson\u2019s disease. J Neurosci 25(4):769\u2013777","journal-title":"J Neurosci"},{"issue":"5","key":"5668_CR149","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1073\/pnas.0536383100","volume":"100","author":"D Kirik","year":"2003","unstructured":"Kirik D et al (2003) Nigrostriatal \u03b1-synucleinopathy induced by viral vector-mediated overexpression of human \u03b1-synuclein: a new primate model of Parkinson\u2019s disease. Proc Natl Acad Sci 100(5):2884\u20132889","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"5668_CR150","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1093\/brain\/awl382","volume":"130","author":"A Eslamboli","year":"2007","unstructured":"Eslamboli A et al (2007) Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain 130(3):799\u2013815","journal-title":"Brain"},{"issue":"1","key":"5668_CR151","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.nbd.2006.11.013","volume":"26","author":"TJ Collier","year":"2007","unstructured":"Collier TJ et al (2007) Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol Dis 26(1):56\u201365","journal-title":"Neurobiol Dis"},{"issue":"6","key":"5668_CR152","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/0197-4580(95)02013-6","volume":"16","author":"GA Gerhardt","year":"1995","unstructured":"Gerhardt GA et al (1995) Age-related changes in potassium-evoked overflow of dopamine in the striatum of the rhesus monkey. Neurobiol Aging 16(6):939\u2013946","journal-title":"Neurobiol Aging"},{"issue":"2","key":"5668_CR153","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/(SICI)1096-9861(19981116)401:2<253::AID-CNE7>3.0.CO;2-X","volume":"401","author":"ME Emborg","year":"1998","unstructured":"Emborg ME et al (1998) Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J Comp Neurol 401(2):253\u2013265","journal-title":"J Comp Neurol"},{"issue":"1","key":"5668_CR154","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13024-019-0321-9","volume":"14","author":"W Yang","year":"2019","unstructured":"Yang W, Li S, Li XJ (2019) A CRISPR monkey model unravels a unique function of PINK1 in primate brains. Mol Neurodegener 14(1):17","journal-title":"Mol Neurodegener"},{"key":"5668_CR155","doi-asserted-by":"publisher","first-page":"20620","DOI":"10.1038\/srep20620","volume":"6","author":"X Wang","year":"2016","unstructured":"Wang X et al (2016) One-step generation of triple gene-targeted pigs using CRISPR\/Cas9 system. Sci Rep 6:20620","journal-title":"Sci Rep"},{"issue":"4","key":"5668_CR156","doi-asserted-by":"publisher","first-page":"469","DOI":"10.24272\/j.issn.2095-8137.2021.023","volume":"42","author":"ZZ Chen","year":"2021","unstructured":"Chen ZZ et al (2021) PINK1 gene mutation by pair truncated sgRNA\/Cas9-D10A in cynomolgus monkeys. Zool Res 42(4):469\u2013477","journal-title":"Zool Res"},{"issue":"9","key":"5668_CR157","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s12264-021-00732-6","volume":"37","author":"H Li","year":"2021","unstructured":"Li H et al (2021) Co-editing PINK1 and DJ-1 genes via Adeno-Associated Virus-Delivered CRISPR\/Cas9 system in adult monkey brain elicits classical parkinsonian phenotype. Neurosci Bull 37(9):1271\u20131288","journal-title":"Neurosci Bull"},{"issue":"8","key":"5668_CR158","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1093\/hmg\/ddu748","volume":"24","author":"Y Niu","year":"2015","unstructured":"Niu Y et al (2015) Early Parkinson\u2019s disease symptoms in \u03b1-synuclein Transgenic monkeys. Hum Mol Genet 24(8):2308\u20132317","journal-title":"Hum Mol Genet"},{"key":"5668_CR159","doi-asserted-by":"crossref","unstructured":"Mallet D et al (2022) A metabolic biomarker predicts Parkinson\u2019s disease at the early stages in patients and animal models. J Clin Invest, 132(4)","DOI":"10.1172\/JCI146400"},{"issue":"7","key":"5668_CR160","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.bbapap.2015.01.007","volume":"1854","author":"X Lin","year":"2015","unstructured":"Lin X et al (2015) Proteomic profiling in MPTP monkey model for early Parkinson disease biomarker discovery. Biochim Biophys Acta 1854(7):779\u2013787","journal-title":"Biochim Biophys Acta"},{"key":"5668_CR161","doi-asserted-by":"crossref","unstructured":"Tomioka I et al (2017) Transgenic monkey model of the polyglutamine diseases recapitulating progressive neurological symptoms. eNeuro, 4(2)","DOI":"10.1523\/ENEURO.0250-16.2017"},{"issue":"12","key":"5668_CR162","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1093\/brain\/awv292","volume":"138","author":"MS Keiser","year":"2015","unstructured":"Keiser MS et al (2015) Broad distribution of ataxin 1 Silencing in rhesus cerebella for spinocerebellar ataxia type 1 therapy. Brain 138(12):3555\u20133566","journal-title":"Brain"},{"key":"5668_CR163","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.nbd.2013.04.003","volume":"56","author":"MS Keiser","year":"2013","unstructured":"Keiser MS et al (2013) RNAi or overexpression: alternative therapies for spinocerebellar ataxia type 1. Neurobiol Dis 56:6\u201313","journal-title":"Neurobiol Dis"},{"issue":"3","key":"5668_CR164","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/mt.2013.279","volume":"22","author":"MS Keiser","year":"2014","unstructured":"Keiser MS, Boudreau RL, Davidson BL (2014) Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy. Mol Ther 22(3):588\u2013595","journal-title":"Mol Ther"},{"issue":"14","key":"5668_CR165","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/S0047-6374(01)00291-3","volume":"122","author":"CD Link","year":"2001","unstructured":"Link CD (2001) Transgenic invertebrate models of age-associated neurodegenerative diseases. Mech Ageing Dev 122(14):1639\u20131649","journal-title":"Mech Ageing Dev"},{"issue":"1","key":"5668_CR166","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/jnc.13532","volume":"137","author":"SB Hannan","year":"2016","unstructured":"Hannan SB et al (2016) Cellular and molecular modifier pathways in tauopathies: the big picture from screening invertebrate models. J Neurochem 137(1):12\u201325","journal-title":"J Neurochem"},{"issue":"34","key":"5668_CR167","doi-asserted-by":"publisher","first-page":"11466","DOI":"10.1021\/bi0506775","volume":"44","author":"T Vandebroek","year":"2005","unstructured":"Vandebroek T et al (2005) Identification and isolation of a hyperphosphorylated, conformationally changed intermediate of human protein Tau expressed in yeast. Biochemistry 44(34):11466\u201311475","journal-title":"Biochemistry"},{"issue":"2","key":"5668_CR168","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3233\/JAD-2009-1145","volume":"18","author":"M Chen","year":"2009","unstructured":"Chen M, Martins RN, Lardelli M (2009) Complex splicing and neural expression of duplicated Tau genes in zebrafish embryos. J Alzheimers Dis 18(2):305\u2013317","journal-title":"J Alzheimers Dis"},{"issue":"41","key":"5668_CR169","doi-asserted-by":"publisher","first-page":"13602","DOI":"10.1021\/bi991453n","volume":"38","author":"U Leimer","year":"1999","unstructured":"Leimer U et al (1999) Zebrafish (Danio rerio) presenilin promotes aberrant amyloid \u03b2-peptide production and requires a critical aspartate residue for its function in amyloidogenesis. Biochemistry 38(41):13602\u201313609","journal-title":"Biochemistry"},{"key":"5668_CR170","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00427-002-0269-5","volume":"212","author":"C Groth","year":"2002","unstructured":"Groth C et al (2002) Identification of a second presenilin gene in zebrafish with similarity to the human Alzheimer\u2019s disease gene presenilin2. Dev Genes Evol 212:486\u2013490","journal-title":"Dev Genes Evol"},{"key":"5668_CR171","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00427-001-0189-9","volume":"211","author":"A Musa","year":"2001","unstructured":"Musa A, Lehrach H, Russo VE (2001) Distinct expression patterns of two zebrafish homologues of the human APP gene during embryonic development. Dev Genes Evol 211:563\u2013567","journal-title":"Dev Genes Evol"},{"issue":"47","key":"5668_CR172","doi-asserted-by":"publisher","first-page":"30121","DOI":"10.1074\/jbc.271.47.30121","volume":"271","author":"AM Fagan","year":"1996","unstructured":"Fagan AM et al (1996) Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein. J Biol Chem 271(47):30121\u201330125","journal-title":"J Biol Chem"},{"issue":"3","key":"5668_CR173","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.cmet.2011.06.018","volume":"14","author":"D Esterhazy","year":"2011","unstructured":"Esterhazy D et al (2011) Bace2 is a \u0392 cell-enriched protease that regulates pancreatic \u0392 cell function and mass. Cell Metabol 14(3):365\u2013377","journal-title":"Cell Metabol"},{"key":"5668_CR174","doi-asserted-by":"publisher","first-page":"861155","DOI":"10.3389\/fnbeh.2022.861155","volume":"16","author":"A Shenoy","year":"2022","unstructured":"Shenoy A et al (2022) The brilliance of the zebrafish model: perception on behavior and Alzheimer\u2019s disease. Front Behav Neurosci 16:861155","journal-title":"Front Behav Neurosci"},{"issue":"4","key":"5668_CR175","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/1096-9861(20001225)428:4<630::AID-CNE4>3.0.CO;2-X","volume":"428","author":"DW Williams","year":"2000","unstructured":"Williams DW, Tyrer M, Shepherd D (2000) Tau and Tau reporters disrupt central projections of sensory neurons in drosophila. J Comp Neurol 428(4):630\u2013640","journal-title":"J Comp Neurol"},{"issue":"17","key":"5668_CR176","doi-asserted-by":"publisher","first-page":"9980","DOI":"10.1073\/pnas.1533448100","volume":"100","author":"BC Kraemer","year":"2003","unstructured":"Kraemer BC et al (2003) Neurodegeneration and defective neurotransmission in a caenorhabditis elegans model of tauopathy. Proc Natl Acad Sci U S A 100(17):9980\u20139985","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"5668_CR177","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1365-2990.2006.00795.x","volume":"33","author":"K Leroy","year":"2007","unstructured":"Leroy K, Yilmaz Z, Brion JP (2007) Increased level of active GSK-3\u03b2 in Alzheimer\u2019s disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol Appl Neurobiol 33(1):43\u201355","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"9","key":"5668_CR178","doi-asserted-by":"publisher","first-page":"e105862","DOI":"10.1371\/journal.pone.0105862","volume":"9","author":"LR Nery","year":"2014","unstructured":"Nery LR et al (2014) Brain intraventricular injection of amyloid-\u03b2 in zebrafish embryo impairs cognition and increases Tau phosphorylation, effects reversed by lithium. PLoS ONE 9(9):e105862","journal-title":"PLoS ONE"},{"key":"5668_CR179","doi-asserted-by":"crossref","unstructured":"Deolankar SC et al (2022) A\u03b242 Expressing Drosophila melanogaster Model for Alzheimer\u2019s Disease: Quantitative Proteomics Identifies Altered Protein Dynamics of Relevance to Neurodegeneration. OMICS: A Journal of Integrative Biology, 26(1): pp. 51\u201363","DOI":"10.1089\/omi.2021.0173"},{"issue":"4\u20135","key":"5668_CR180","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000080983","volume":"1","author":"E Braungart","year":"2004","unstructured":"Braungart E et al (2004) Caenorhabditis elegans MPP\u2009+\u2009model of Parkinson\u2019s disease for high-throughput drug screenings. Neurodegener Dis 1(4\u20135):175\u2013183","journal-title":"Neurodegener Dis"},{"key":"5668_CR181","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1146\/annurev.ne.11.030188.000501","volume":"11","author":"IJ Kopin","year":"1988","unstructured":"Kopin IJ, Markey SP (1988) MPTP toxicity: implications for research in Parkinson\u2019s disease. Annu Rev Neurosci 11:81\u201396","journal-title":"Annu Rev Neurosci"},{"issue":"6","key":"5668_CR182","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/00002826-198612000-00001","volume":"9","author":"JW Langston","year":"1986","unstructured":"Langston JW, Irwin I (1986) MPTP: current concepts and controversies. Clin Neuropharmacol 9(6):485\u2013507","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"5668_CR183","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3233\/JPD-171258","volume":"8","author":"JF Cooper","year":"2018","unstructured":"Cooper JF, Van Raamsdonk JM (2018) Modeling Parkinson\u2019s disease in C. elegans. J Parkinson\u2019s Disease 8(1):17\u201332","journal-title":"J Parkinson\u2019s Disease"},{"key":"5668_CR184","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3389\/fneur.2018.00228","volume":"9","author":"Y Xiong","year":"2018","unstructured":"Xiong Y, Yu J (2018) Modeling Parkinson\u2019s disease in drosophila: what have we learned for dominant traits?? Front Neurol 9:228\u2013228","journal-title":"Front Neurol"},{"issue":"1","key":"5668_CR185","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1254\/jjp.78.23","volume":"78","author":"Y Kitamura","year":"1998","unstructured":"Kitamura Y, Kakimura J, Taniguchi T (1998) Protective effect of Talipexole on MPTP-treated planarian, a unique parkinsonian worm model. Jpn J Pharmacol 78(1):23\u201329","journal-title":"Jpn J Pharmacol"},{"issue":"6","key":"5668_CR186","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.ntt.2004.06.014","volume":"26","author":"S Bretaud","year":"2004","unstructured":"Bretaud S, Lee S, Guo S (2004) Sensitivity of zebrafish to environmental toxins implicated in Parkinson\u2019s disease. Neurotoxicol Teratol 26(6):857\u2013864","journal-title":"Neurotoxicol Teratol"},{"key":"5668_CR187","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s12640-017-9778-x","volume":"32","author":"Y Vijayanathan","year":"2017","unstructured":"Vijayanathan Y et al (2017) 6-OHDA-lesioned adult zebrafish as a useful Parkinson\u2019s disease model for dopaminergic neuroregeneration. Neurotox Res 32:496\u2013508","journal-title":"Neurotox Res"},{"issue":"2","key":"5668_CR188","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1089\/zeb.2013.0923","volume":"11","author":"JW Bortolotto","year":"2014","unstructured":"Bortolotto JW et al (2014) Long-term exposure to Paraquat alters behavioral parameters and dopamine levels in adult zebrafish (Danio rerio). Zebrafish 11(2):142\u2013153","journal-title":"Zebrafish"},{"issue":"20","key":"5668_CR189","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1093\/hmg\/ddr312","volume":"20","author":"Z Liu","year":"2011","unstructured":"Liu Z et al (2011) Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in caenorhabditis elegans and drosophila Parkinson\u2019s disease models. Hum Mol Genet 20(20):3933\u20133942","journal-title":"Hum Mol Genet"},{"issue":"12","key":"5668_CR190","doi-asserted-by":"publisher","first-page":"8306","DOI":"10.1007\/s12035-019-01667-w","volume":"56","author":"AJ Edson","year":"2019","unstructured":"Edson AJ et al (2019) Dysregulation in the brain protein profile of zebrafish lacking the Parkinson\u2019s Disease-Related protein DJ-1. Mol Neurobiol 56(12):8306\u20138322","journal-title":"Mol Neurobiol"},{"issue":"33","key":"5668_CR191","doi-asserted-by":"publisher","first-page":"8199","DOI":"10.1523\/JNEUROSCI.0979-08.2008","volume":"28","author":"O Anichtchik","year":"2008","unstructured":"Anichtchik O et al (2008) Loss of PINK1 function affects development and results in neurodegeneration in zebrafish. J Neurosci 28(33):8199\u20138207","journal-title":"J Neurosci"},{"issue":"6","key":"5668_CR192","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1093\/brain\/awp108","volume":"132","author":"L Flinn","year":"2009","unstructured":"Flinn L et al (2009) Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio). Brain 132(6):1613\u20131623","journal-title":"Brain"},{"issue":"6808","key":"5668_CR193","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/35040584","volume":"408","author":"P Fernandez-Funez","year":"2000","unstructured":"Fernandez-Funez P et al (2000) Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 408(6808):101\u2013106","journal-title":"Nature"},{"issue":"5","key":"5668_CR194","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1093\/hmg\/ddt524","volume":"23","author":"SS Barclay","year":"2013","unstructured":"Barclay SS et al (2013) Systems biology analysis of drosophila in vivo screen data elucidates core networks for DNA damage repair in SCA1. Hum Mol Genet 23(5):1345\u20131364","journal-title":"Hum Mol Genet"},{"issue":"14","key":"5668_CR195","doi-asserted-by":"publisher","first-page":"7351","DOI":"10.3390\/ijms22147351","volume":"22","author":"MA Elsaey","year":"2021","unstructured":"Elsaey MA, Namikawa K, K\u00f6ster RW (2021) Genetic modeling of the neurodegenerative disease spinocerebellar ataxia type 1 in zebrafish. Int J Mol Sci 22(14):7351","journal-title":"Int J Mol Sci"},{"key":"5668_CR196","doi-asserted-by":"crossref","unstructured":"Morton DB (2023) A Model Framework for the Estimation of Animal \u2018Suffering\u2019: Its Use in Predicting and Retrospectively Assessing the Impact of Experiments on Animals. Anim (Basel), 13(5)","DOI":"10.3390\/ani13050800"},{"key":"5668_CR197","doi-asserted-by":"crossref","unstructured":"Semple BD et al (2013) Brain development in rodents and humans: identifying benchmarks of maturation and vulnerability to injury across species. Prog Neurobiol, 106\u2013107:1\u201316","DOI":"10.1016\/j.pneurobio.2013.04.001"},{"key":"5668_CR198","first-page":"315","volume-title":"Vivo animal models development and their limitations for brain Research, in Application of nanocarriers in brain delivery of therapeutics","author":"SV Mangrulkar","year":"2024","unstructured":"Mangrulkar SV et al (2024) Vivo animal models development and their limitations for brain Research, in Application of nanocarriers in brain delivery of therapeutics. Springer, Nature Singapore: Singapore, pp 315\u2013339. A. Alexander, Editor"},{"issue":"2","key":"5668_CR199","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2174\/156720509787602834","volume":"6","author":"M Sarasa","year":"2009","unstructured":"Sarasa M, Pesini P (2009) Natural non-trasgenic animal models for research in Alzheimer\u2019s disease. Curr Alzheimer Res 6(2):171\u2013178","journal-title":"Curr Alzheimer Res"},{"issue":"22","key":"5668_CR200","doi-asserted-by":"publisher","first-page":"21418","DOI":"10.1074\/jbc.M413955200","volume":"280","author":"L Chen","year":"2005","unstructured":"Chen L et al (2005) Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J Biol Chem 280(22):21418\u201321426","journal-title":"J Biol Chem"},{"key":"5668_CR201","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-020-00399-z","volume":"15","author":"L Serneels","year":"2020","unstructured":"Serneels L et al (2020) Modeling the \u03b2-secretase cleavage site and humanizing amyloid-beta precursor protein in rat and mouse to study Alzheimer\u2019s disease. Mol Neurodegeneration 15:1\u201311","journal-title":"Mol Neurodegeneration"},{"issue":"2","key":"5668_CR202","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3233\/JAD-171058","volume":"62","author":"DCS Tan","year":"2018","unstructured":"Tan DCS et al (2018) Generation of a new Tau knockout (tau\u2206ex1) line using CRISPR\/Cas9 genome editing in mice. J Alzheimers Dis 62(2):571\u2013578","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"5668_CR203","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s12015-024-10701-x","volume":"20","author":"A Vashishat","year":"2024","unstructured":"Vashishat A et al (2024) Alternatives of animal models for biomedical research: a comprehensive review of modern approaches. Stem Cell Reviews Rep 20(4):881\u2013899","journal-title":"Stem Cell Reviews Rep"},{"key":"5668_CR204","doi-asserted-by":"publisher","first-page":"103131","DOI":"10.1016\/j.jddst.2022.103131","volume":"68","author":"SY Lee","year":"2022","unstructured":"Lee SY et al (2022) Alternative experimental approaches to reduce animal use in biomedical studies. J Drug Deliv Sci Technol 68:103131","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"5668_CR205","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1038\/s41467-024-46554-8","volume":"15","author":"S Amartumur","year":"2024","unstructured":"Amartumur S et al (2024) Neuropathogenesis-on-chips for neurodegenerative diseases. Nat Commun 15(1):2219","journal-title":"Nat Commun"},{"key":"5668_CR206","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jconrel.2015.07.020","volume":"215","author":"KA Fitzgerald","year":"2015","unstructured":"Fitzgerald KA et al (2015) Life in 3D is never flat: 3D models to optimise drug delivery. J Controlled Release 215:39\u201354","journal-title":"J Controlled Release"},{"issue":"11","key":"5668_CR207","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.3390\/cells8111438","volume":"8","author":"G Costamagna","year":"2019","unstructured":"Costamagna G et al (2019) iPSCs-based neural 3D systems: a multidimensional approach for disease modeling and drug discovery. Cells 8(11):1438","journal-title":"Cells"},{"key":"5668_CR208","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3389\/fnsyn.2018.00015","volume":"10","author":"H Wang","year":"2018","unstructured":"Wang H (2018) Modeling neurological diseases with human brain organoids. Front Synaptic Neurosci 10:15","journal-title":"Front Synaptic Neurosci"},{"key":"5668_CR209","doi-asserted-by":"publisher","first-page":"1419526","DOI":"10.3389\/fncel.2024.1419526","volume":"18","author":"N Urrestizala-Arenaza","year":"2024","unstructured":"Urrestizala-Arenaza N et al (2024) Limitations of human brain organoids to study neurodegenerative diseases: a manual to survive. Front Cell Neurosci 18:1419526","journal-title":"Front Cell Neurosci"},{"key":"5668_CR210","doi-asserted-by":"crossref","unstructured":"Moy AB et al (2023) The challenges to advancing induced pluripotent stem cell-Dependent cell replacement therapy. Med Res Arch, 11(11)","DOI":"10.18103\/mra.v11i11.4784"},{"key":"5668_CR211","doi-asserted-by":"publisher","first-page":"1188905","DOI":"10.3389\/fcell.2023.1188905","volume":"11","author":"Z Xu","year":"2023","unstructured":"Xu Z et al (2023) Merits and challenges of iPSC-derived organoids for clinical applications. Front Cell Dev Biol 11:1188905","journal-title":"Front Cell Dev Biol"},{"issue":"12","key":"5668_CR212","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11910-017-0802-6","volume":"17","author":"EMM Quigley","year":"2017","unstructured":"Quigley EMM (2017) Microbiota-Brain-Gut axis and neurodegenerative diseases. Curr Neurol Neurosci Rep 17(12):94","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"3","key":"5668_CR213","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/aor.14503","volume":"47","author":"JJ Han","year":"2023","unstructured":"Han JJ (2023) FDA modernization act 2.0 allows for alternatives to animal testing. Artif Organs 47(3):449\u2013450","journal-title":"Artif Organs"},{"issue":"1","key":"5668_CR214","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/toxsci\/kfae122","volume":"203","author":"SA Carratt","year":"2024","unstructured":"Carratt SA et al (2024) An industry perspective on the FDA modernization act 2.0\/3.0: potential next steps for sponsors to reduce animal use in drug development. Toxicol Sci 203(1):28\u201334","journal-title":"Toxicol Sci"},{"key":"5668_CR215","doi-asserted-by":"crossref","unstructured":"Zushin PH, Mukherjee S, Wu JC (2023) FDA Modernization Act 2.0: transitioning beyond animal models with human cells, organoids, and AI\/ML-based approaches. J Clin Invest, 133(21)","DOI":"10.1172\/JCI175824"},{"issue":"1","key":"5668_CR216","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/0250-474X.89750","volume":"73","author":"T Arora","year":"2011","unstructured":"Arora T et al (2011) Substitute of animals in drug research: an approach towards fulfillment of 4R\u2019s. Indian J Pharm Sci 73(1):1\u20136","journal-title":"Indian J Pharm Sci"},{"issue":"2","key":"5668_CR217","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4103\/ijp.ijp_223_23","volume":"55","author":"V Mahalmani","year":"2023","unstructured":"Mahalmani V, Prakash A, Medhi B (2023) Do alternatives to animal experimentation replace preclinical research? Indian J Pharmacol 55(2):71\u201375","journal-title":"Indian J Pharmacol"},{"issue":"6","key":"5668_CR218","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s12015-024-10723-5","volume":"20","author":"G Park","year":"2024","unstructured":"Park G et al (2024) Replacing animal testing with stem Cell-Organoids: advantages and limitations. Stem Cell Rev Rep 20(6):1375\u20131386","journal-title":"Stem Cell Rev Rep"},{"key":"5668_CR219","doi-asserted-by":"publisher","first-page":"101339","DOI":"10.1016\/j.arr.2021.101339","volume":"68","author":"KI Avgerinos","year":"2021","unstructured":"Avgerinos KI, Ferrucci L, Kapogiannis D (2021) Effects of monoclonal antibodies against amyloid-\u03b2 on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer\u2019s disease. Ageing Res Rev 68:101339","journal-title":"Ageing Res Rev"},{"issue":"1","key":"5668_CR220","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1750-1326-2-20","volume":"2","author":"I Lefterov","year":"2007","unstructured":"Lefterov I et al (2007) Expression profiling in APP23 mouse brain: Inhibition of A\u03b2 amyloidosis and inflammation in response to LXR agonist treatment. Mol Neurodegeneration 2(1):20","journal-title":"Mol Neurodegeneration"},{"issue":"26","key":"5668_CR221","doi-asserted-by":"publisher","first-page":"6213","DOI":"10.1523\/JNEUROSCI.0664-05.2005","volume":"25","author":"RE Hartman","year":"2005","unstructured":"Hartman RE et al (2005) Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer\u2019s disease. J Neurosci 25(26):6213\u20136220","journal-title":"J Neurosci"},{"issue":"1","key":"5668_CR222","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00213-005-2230-6","volume":"181","author":"H Dong","year":"2005","unstructured":"Dong H et al (2005) Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer\u2019s disease. Psychopharmacology 181(1):145\u2013152","journal-title":"Psychopharmacology"},{"key":"5668_CR223","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3389\/fnins.2019.00472","volume":"13","author":"DD Li","year":"2019","unstructured":"Li DD et al (2019) Meta-Analysis of randomized controlled trials on the efficacy and safety of donepezil, galantamine, Rivastigmine, and memantine for the treatment of Alzheimer\u2019s disease. Front Neurosci 13:472","journal-title":"Front Neurosci"},{"issue":"7","key":"5668_CR224","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/nm1423","volume":"12","author":"J McLaurin","year":"2006","unstructured":"McLaurin J et al (2006) Cyclohexanehexol inhibitors of A\u03b2 aggregation prevent and reverse alzheimer phenotype in a mouse model. Nat Med 12(7):801\u2013808","journal-title":"Nat Med"},{"key":"5668_CR225","doi-asserted-by":"crossref","unstructured":"Ma K, Thomason LAM, McLaurin J (2012) scyllo-Inositol, preclinical, and clinical data for Alzheimer\u2019s Disease, in Advances in Pharmacology. Academic, pp 177\u2013212. E.K. Michaelis and M.L. Michaelis, Editors","DOI":"10.1016\/B978-0-12-394816-8.00006-4"},{"issue":"12","key":"5668_CR226","doi-asserted-by":"publisher","first-page":"6414","DOI":"10.1039\/C8FO00964C","volume":"9","author":"LF Zhang","year":"2018","unstructured":"Zhang LF et al (2018) Resveratrol alleviates motor and cognitive deficits and neuropathology in the A53T \u03b1-synuclein mouse model of Parkinson\u2019s disease. Food Funct 9(12):6414\u20136426","journal-title":"Food Funct"},{"issue":"1","key":"5668_CR227","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3390\/biomedicines12010130","volume":"12","author":"KKN Tran","year":"2024","unstructured":"Tran KKN et al (2024) Levodopa rescues retinal function in the Transgenic A53T Alpha-Synuclein model of Parkinson\u2019s disease. Biomedicines 12(1):130","journal-title":"Biomedicines"},{"issue":"8","key":"5668_CR228","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.2174\/1570159X15666170510143821","volume":"16","author":"N Tambasco","year":"2018","unstructured":"Tambasco N, Romoli M, Calabresi P (2018) Levodopa in Parkinson\u2019s disease: current status and future developments. Curr Neuropharmacol 16(8):1239\u20131252","journal-title":"Curr Neuropharmacol"},{"issue":"7","key":"5668_CR229","doi-asserted-by":"publisher","first-page":"e1001609","DOI":"10.1371\/journal.pbio.1001609","volume":"11","author":"KK Tsilidis","year":"2013","unstructured":"Tsilidis KK et al (2013) Evaluation of excess significance bias in animal studies of neurological diseases. PLoS Biol 11(7):e1001609","journal-title":"PLoS Biol"},{"issue":"40","key":"5668_CR230","doi-asserted-by":"publisher","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","volume":"26","author":"H Oakley","year":"2006","unstructured":"Oakley H et al (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in Transgenic mice with five Familial Alzheimer\u2019s disease mutations: potential factors in amyloid plaque formation. J Neurosci 26(40):10129\u201310140","journal-title":"J Neurosci"},{"issue":"9","key":"5668_CR231","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/sj.embor.7400784","volume":"7","author":"R Radde","year":"2006","unstructured":"Radde R et al (2006) Abeta42-driven cerebral amyloidosis in Transgenic mice reveals early and robust pathology. EMBO Rep 7(9):940\u2013946","journal-title":"EMBO Rep"},{"issue":"5284","key":"5668_CR232","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1126\/science.274.5284.99","volume":"274","author":"K Hsiao","year":"1996","unstructured":"Hsiao K et al (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in Transgenic mice. Science 274(5284):99\u2013102","journal-title":"Science"},{"issue":"5","key":"5668_CR233","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nn.3697","volume":"17","author":"T Saito","year":"2014","unstructured":"Saito T et al (2014) Single app knock-in mouse models of Alzheimer\u2019s disease. Nat Neurosci 17(5):661\u2013663","journal-title":"Nat Neurosci"},{"issue":"1","key":"5668_CR234","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13024-022-00547-7","volume":"17","author":"D Xia","year":"2022","unstructured":"Xia D et al (2022) Novel app knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia. Mol Neurodegeneration 17(1):41","journal-title":"Mol Neurodegeneration"},{"issue":"1","key":"5668_CR235","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1038\/s41467-021-22624-z","volume":"12","author":"D Baglietto-Vargas","year":"2021","unstructured":"Baglietto-Vargas D et al (2021) Generation of a humanized A\u03b2 expressing mouse demonstrating aspects of Alzheimer\u2019s disease-like pathology. Nat Commun 12(1):2421","journal-title":"Nat Commun"},{"key":"5668_CR236","doi-asserted-by":"publisher","first-page":"838436","DOI":"10.3389\/fnagi.2022.838436","volume":"14","author":"KE Foley","year":"2022","unstructured":"Foley KE et al (2022) The APOE (\u03b53\/\u03b54) genotype drives distinct gene signatures in the cortex of young mice. Front Aging Neurosci 14:838436","journal-title":"Front Aging Neurosci"},{"issue":"10","key":"5668_CR237","doi-asserted-by":"publisher","first-page":"4471","DOI":"10.1073\/pnas.89.10.4471","volume":"89","author":"JA Piedrahita","year":"1992","unstructured":"Piedrahita JA et al (1992) Generation of mice carrying a mutant Apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci U S A 89(10):4471\u20134475","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"5668_CR238","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/hmg\/ddx366","volume":"27","author":"SS Kang","year":"2018","unstructured":"Kang SS et al (2018) Behavioral and transcriptomic analysis of Trem2-null mice: not all knockout mice are created equal. Hum Mol Genet 27(2):211\u2013223","journal-title":"Hum Mol Genet"},{"issue":"5456","key":"5668_CR239","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1126\/science.287.5456.1265","volume":"287","author":"E Masliah","year":"2000","unstructured":"Masliah E et al (2000) Dopaminergic loss and inclusion body formation in \u03b1-Synuclein mice: implications for neurodegenerative disorders. Science 287(5456):1265\u20131269","journal-title":"Science"},{"issue":"5","key":"5668_CR240","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/jnr.10231","volume":"68","author":"E Rockenstein","year":"2002","unstructured":"Rockenstein E et al (2002) Differential neuropathological alterations in Transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res 68(5):568\u2013578","journal-title":"J Neurosci Res"},{"issue":"5","key":"5668_CR241","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.neurobiolaging.2013.11.008","volume":"35","author":"LJ Martin","year":"2014","unstructured":"Martin LJ et al (2014) Mitochondrial permeability transition pore regulates Parkinson\u2019s disease development in mutant \u03b1-synuclein Transgenic mice. Neurobiol Aging 35(5):1132\u20131152","journal-title":"Neurobiol Aging"},{"issue":"7","key":"5668_CR242","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/nn.2349","volume":"12","author":"Y Li","year":"2009","unstructured":"Li Y et al (2009) Mutant LRRK2(R1441G) BAC Transgenic mice recapitulate Cardinal features of Parkinson\u2019s disease. Nat Neurosci 12(7):826\u2013828","journal-title":"Nat Neurosci"},{"key":"5668_CR243","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.nbd.2015.02.031","volume":"78","author":"M Yue","year":"2015","unstructured":"Yue M et al (2015) Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol Dis 78:172\u2013195","journal-title":"Neurobiol Dis"},{"issue":"44","key":"5668_CR244","doi-asserted-by":"publisher","first-page":"43628","DOI":"10.1074\/jbc.M308947200","volume":"278","author":"MS Goldberg","year":"2003","unstructured":"Goldberg MS et al (2003) Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 278(44):43628\u201343635","journal-title":"J Biol Chem"},{"issue":"27","key":"5668_CR245","doi-asserted-by":"publisher","first-page":"11441","DOI":"10.1073\/pnas.0702717104","volume":"104","author":"T Kitada","year":"2007","unstructured":"Kitada T et al (2007) Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc Natl Acad Sci U S A 104(27):11441\u201311446","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5668_CR246","doi-asserted-by":"crossref","unstructured":"Ekstrand MI et al (2007) Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proceedings of the National Academy of Sciences, 104(4): pp. 1325\u20131330","DOI":"10.1073\/pnas.0605208103"},{"key":"5668_CR247","first-page":"421","volume":"5","author":"U Ungerstedt","year":"1974","unstructured":"Ungerstedt U, Ljungberg T, Steg G (1974) Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons. Adv Neurol 5:421\u2013426","journal-title":"Adv Neurol"},{"issue":"4587","key":"5668_CR248","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1126\/science.6823561","volume":"219","author":"JW Langston","year":"1983","unstructured":"Langston JW et al (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219(4587):979\u2013980","journal-title":"Science"},{"issue":"1\u20132","key":"5668_CR249","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0006-8993(01)02577-X","volume":"906","author":"K Shimizu","year":"2001","unstructured":"Shimizu K et al (2001) Carrier-mediated processes in blood\u2013brain barrier penetration and neural uptake of Paraquat. Brain Res 906(1\u20132):135\u2013142","journal-title":"Brain Res"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-025-05668-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-025-05668-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-025-05668-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:29:59Z","timestamp":1744172999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-025-05668-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":249,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5668"],"URL":"https:\/\/doi.org\/10.1007\/s00018-025-05668-y","relation":{},"ISSN":["1420-9071"],"issn-type":[{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"16 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Authors consent to publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors declare no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"147"}}